SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $1,220,950 | +5.8% | 42,189 | +0.8% | 0.03% | 0.0% |
Q3 2023 | $1,153,915 | +148.2% | 41,854 | +170.7% | 0.03% | +200.0% |
Q2 2023 | $464,848 | -19.7% | 15,464 | -3.2% | 0.01% | -31.2% |
Q1 2023 | $578,738 | -18.6% | 15,974 | -19.9% | 0.02% | -20.0% |
Q4 2022 | $711,188 | +8.2% | 19,938 | +2.8% | 0.02% | -9.1% |
Q3 2022 | $657,000 | +16.7% | 19,398 | -0.4% | 0.02% | +37.5% |
Q2 2022 | $563,000 | -8.5% | 19,472 | +2.3% | 0.02% | +33.3% |
Q1 2022 | $615,000 | -54.8% | 19,028 | -59.2% | 0.01% | -53.8% |
Q4 2021 | $1,360,000 | +11.3% | 46,635 | +1.8% | 0.03% | -16.1% |
Q3 2021 | $1,222,000 | +9.9% | 45,822 | +26.9% | 0.03% | -11.4% |
Q2 2021 | $1,112,000 | +30.1% | 36,105 | +10.5% | 0.04% | +9.4% |
Q1 2021 | $855,000 | +20.1% | 32,672 | +15.4% | 0.03% | -3.0% |
Q4 2020 | $712,000 | +33.8% | 28,310 | +10.8% | 0.03% | +10.0% |
Q3 2020 | $532,000 | +6.0% | 25,550 | +20.9% | 0.03% | -63.9% |
Q2 2020 | $502,000 | – | 21,136 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |